Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001193125-26-445289·Nautilus Biotechnology, Inc.
Schedule 13D ownership disclosure
Nautilus Biotechnology, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 63909J108
Event date: 2026-10-05
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Perceptive Advisors LLCReported CIK 0001224962
Shares: 4,944,512.00 · Class: 3.9%
- Joseph EdelmanReported CIK 0001164426
Shares: 4,944,512.00 · Class: 3.9%
- Perceptive Life Sciences Master Fund, Ltd.Reported CIK 0001249675
Shares: 4,778,652.00 · Class: 3.8%
- C2 Life Sciences LLCReported CIK 0001890152
Shares: 165,860 · Class: 0.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-26-445289
- Form type
- SCHEDULE 13D/A
- Filer
- Nautilus Biotechnology, Inc.
- CIK
- CIK 1808805
- Filed
- Nov 03, 2026
- Reporting period
- Oct 05, 2026
- Description
- Schedule 13D beneficial ownership